YHC 1102
Alternative Names: YHC-1102Latest Information Update: 09 Jun 2021
At a glance
- Originator Yuhan
- Developer Gilead Sciences; Yuhan
- Class Anti-inflammatories; Antifibrotics; Hepatoprotectants; Small molecules
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Non-alcoholic steatohepatitis